29 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
products, and the company culture. Cintia was instrumental in designing and steering our commercial model design and her leadership will be critical
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 May 19
Adaptimmune TRANSFORMING T CELL THERAPY Clinical and Business Update
8:11am
(DCs) and T-cells in co-culture with – Improved killing of MAGE-A4+ cells (shown below)
SURPASS Study (ADP-A2M4CD8) next-gen Study start planned
8-K
EX-10.2
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
the appropriate culture, values and behaviours in the boardroom and beyond;
insist on receiving high-quality information sufficiently in advance of Board
8-K
EX-10.3
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
and probity and support the chairman, directors and senior management in instilling the appropriate culture, values and behaviours in the boardroom
8-K
EX-10.4
ef42nzfqs 819
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-10.4
6e4vr7ejfsvp7 sqx76
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
xnm59g9co zqm7ap
6 Jul 18
Departure of Directors or Certain Officers
5:00pm
S-4/A
r7p60 uof7i5
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm